Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label active-controlled trial of flonotinib maleate tablets in intermediate-2/high-risk myelofibrosis
CTR20241632Phase 2Active
- Sponsor
- Zeling Biopharma
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of flonotinib in primary myelofibrosis (PMF), myelofibrosis (MF), sponsored by Zeling Biopharma. Started Jul 2024; status: active.
02
Drugs
flonotinib
03
Conditions
primary myelofibrosis (PMF)myelofibrosis (MF)
Beyond the preview
Go deeper on CTR20241632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241632.